New Haven, CTNCT07101328Now EnrollingIRB Ready

Lymphoma, Non-Hodgkin Clinical Trial in New Haven, CT

Access cutting-edge lymphoma, non-hodgkin treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Eli Lilly and Company

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access lymphoma, non-hodgkin specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related lymphoma, non-hodgkin treatment provided free

Apply for This New Haven Location

Check if you qualify for this lymphoma, non-hodgkin clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Lymphoma, Non-Hodgkin Study in New Haven

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

Sponsor: Eli Lilly and Company

Who Can Participate

Inclusion Criteria

Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma.
Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator.
Participants with select tumor types must have measurable or assessable disease as defined below:
Participants with lymphoma must have at least 1 bi-dimensionally measurable lesion or in the absence of measurable lymphadenopathy, documentation of bone marrow involvement.
Participants with Waldenstrom macroglobulinemia (WM) must have measurable disease, defined as the presence of serum IgM with a minimum IgM level of greater than (\>)2 times (×) upper limit of normal (ULN) based on local laboratory testing.
Must be able to comply with inpatient/outpatient treatment, laboratory monitoring, and required clinic visits for the duration of trial participation.
Must have adequate organ function. Phase 1 Dose Escalation (Cohort A) Participants - Must have histologically confirmed relapsed/refractory B-cell malignancy. Phase 1 Dose Optimization (Cohort B) Participants \- Must have histologically confirmed relapsed/refractory diffuse large B-cell lymphoma (DLBCL) de novo or transformed from follicular lymphoma (FL).

Exclusion Criteria

All Participants
Known or suspected peripheral blood involvement by malignant cells with an absolute lymphocyte count of greater than or equal to (≥) 5000 cells per microliter (μL).
Known or suspected central nervous system (CNS) involvement by systemic lymphoma.
Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
Any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 2 at the time of starting trial treatment except for alopecia.
Autologous stem cell transplantation within 100 days of this study for post autologous transplant individuals.
Residual symptoms of neurotoxicity or cytopenias from prior chimeric antigen receptor T-cell therapy (CAR-T) or bispecifics. Exception: Cytopenia related to prior CAR-T or bispecifics allowed if they meet the adequate organ function criteria.
Known or suspected history of macrophage activation syndrome or hemophagocytic lymphohistiocytosis (HLH).
Active second malignancies, unless in remission, with life expectancy greater than 2 years with Sponsor approval.
History of autoimmune disease
Significant cardiovascular disease
Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process
Vaccination with a live vaccine within 4 weeks prior to signing informed consent form (ICF).
Have current or had a history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins).
Prior treatment with B-cell activating factor receptor (BAFF-R) directed therapies (e.g., monoclonal antibody, CAR-T or bispecific antibody).
Pregnant and/or planning to breastfeed during the trial or within 90 days of the last dose of study intervention.
Known hypersensitivity to any component or excipient of LY4152199.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT07101328) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lymphoma, Non-Hodgkin Treatment Options in New Haven, CT

If you're searching for lymphoma, non-hodgkin treatment options in New Haven, CT, this clinical trial (NCT07101328) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lymphoma, non-hodgkin specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lymphoma, non-hodgkin clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in New Haven, CT

See all lymphoma clinical trials recruiting in New Haven — not just this study.

Browse Lymphoma Trials in New Haven →

Browse More Trials by Condition

Lymphoma TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT